Bioasis Technologies Inc. (OTCMKTS:BIOAF) Short Interest Down 23.3% in July
Bioasis Technologies Inc. (OTCMKTS:BIOAF) Short Interest Down 23.3% in July
Bioasis Technologies Inc. (OTCMKTS:BIOAF – Get Rating) was the recipient of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totalling 34,600 shares, a decrease of 23.3% from the July 15th total of 45,100 shares. Based on an average daily trading volume, of 29,000 shares, the short-interest ratio is presently 1.2 days.
绿洲生物科技股份有限公司(场外交易代码：BIOAF-GET Rating)是7月份空头股数销量大幅下降的接收方。截至7月31日，空头股数共有3.46万股，比7月15日的4.51万股减少了23.3%。以日均成交量2.9万股计算，目前短息比为1.2天。
Bioasis Technologies Stock Performance
BiOASIS科技股表现
BIOAF stock opened at $0.12 on Monday. The company's 50 day moving average price is $0.13 and its 200 day moving average price is $0.17. Bioasis Technologies has a fifty-two week low of $0.10 and a fifty-two week high of $0.28. The firm has a market capitalization of $9.50 million, a price-to-earnings ratio of -2.99 and a beta of 0.19.
周一，BIOAF的股票开盘报0.12美元。该公司的50日移动均线价格为0.13美元，其200日移动均线价格为0.17美元。BiOasis Technologies的股价为0.10美元，为52周低点，52周高位为0.28美元。该公司市值为950万美元，市盈率为-2.99倍，贝塔系数为0.19。
Bioasis Technologies (OTCMKTS:BIOAF – Get Rating) last announced its quarterly earnings results on Tuesday, June 14th. The company reported ($0.01) earnings per share (EPS) for the quarter. Equities analysts forecast that Bioasis Technologies will post -0.05 EPS for the current fiscal year.
BiOasis Technologies(OTCMKTS：BIOAF-GET Rating)最近一次公布季度收益是在6月14日(星期二)。该公司公布了该季度每股收益(EPS)(0.01美元)。股票分析师预测，BiOasis Technologies本财年的每股收益将达到0.05欧元。
Bioasis Technologies Company Profile
BiOASIS技术公司简介
Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases.
BiOASIS技术公司是一家处于发展阶段的生物制药公司，致力于神经疾病和障碍的诊断和治疗产品的研究和开发。它正在开发xB3，这是一种通过血脑屏障(BBB)运输治疗剂的平台技术；以及治疗中枢神经系统疾病(CNS)，包括脑癌，以及代谢和神经退行性疾病。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Bioasis Technologies (BIOAF)
- Here is a Simple 4 Stock Portfolio that Can Outperform the Market
- Is AMC Entertainment Pulling a Fast One on the APEs?
- Here's How the Inflation Reduction Act Energizes Power Stock
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- 免费获取StockNews.com关于BiOASIS技术的研究报告(BIOAF)
- 以下是一个简单的4只股票投资组合，它可以跑赢大盘
- AMC娱乐公司是在对猩猩采取快速行动吗？
- 以下是《降低通胀法案》如何提振电力库存
- 值得关注的两场重要的零售股大战
- MarketBeat：回顾中的一周2012-8-8
Receive News & Ratings for Bioasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《BiOASIS技术日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收最新新闻和分析师对BiOasis Technologies及相关公司的评级的每日摘要。
译文内容由第三方软件翻译。